

Breaking Barriers in Oncology Research

# A Journey of Overcoming Obstacles and Maximizing Patient Enrollment

By leveraging the expertise of our *Study Physician Service*, we facilitated enhanced communication, strategic planning, and targeted support, ultimately advancing the study's objectives and benefiting patients with recurrent platinum-sensitive cancers.

## Phase II study

A multicenter, open-label, phase II study aimed at evaluating the effectiveness of a combination therapy involving carboplatin and an unnamed antibody-drug conjugate (ADC). The study targets patients diagnosed with recurrent, platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers. Eligible participants are those who have a positive status for a specific receptor and have previously received one line of platinum-based chemotherapy.

## Challenge

The study aimed to enroll over 110+ patients by a set deadline. During a key phase, the trial faced a significant setback. Despite thorough planning, only a fraction of the required patients had been enrolled. The primary cause of this delay was the prolonged approval process in several selected countries. Additionally, the operational countries and trial sites did not contribute as many patients as anticipated.

## Solution

To address this challenge, Ergomed Clinical Research implemented a strategic solution: the **Study Physician Service (SPS)**. This service involved our physicians actively engaging with investigators to discuss the study, focusing on enrollment hurdles and potential solutions. These discussions occurred remotely via emails and phone calls, ensuring comprehensive support to trial sites.

*Our SPS specialists worked closely with investigators to create tailored inclusion plans that improved patient pathways and site activities, enhancing enrollment rates.* They maintained regular contact with sites to monitor progress and quickly address recruitment delays. By fostering positive relationships and sharing successful recruitment strategies from other sites, our specialists motivated PIs and study teams. The recognition of SPS by the PIs enhanced their protocol understanding and provided essential support for selecting appropriate trial participants.

## Outcome

Due to the implementation of the *Study Physician Service*, Ergomed Clinical Research not only met but *surpassed its initial targets*, rapidly *filling all available trial slots* shortly after *successful screening completion*.

Our proactive approach and unwavering commitment to overcoming obstacles ensured seamless progression and standout success in this multicenter clinical trial.